WHO declares Ebola outbreak in DRC and Uganda global health emergency

On Sunday, the World Health Organization made an official declaration that shifted the status of an Ebola outbreak unfolding across the Democratic Republic of Congo and Uganda. The virus, identified as the Bundibugyo strain, was now classified as a public health emergency of international concern—a designation that signals serious risk but stops short of pandemic status. By Saturday, the numbers told a grim story: eighty suspected deaths, eight cases confirmed through laboratory testing, and two hundred forty-six suspected infections concentrated in Ituri province in the eastern reaches of the DRC.

The outbreak had already crossed into at least three separate health zones—Bunia, Rwampara, and Mongbwalu—and the WHO warned that neighboring countries sharing land borders with the DRC faced elevated risk of further spread. The virus does not travel through the air, which limits its contagiousness compared to respiratory illnesses, but it moves efficiently through direct contact with blood, vomit, and other body fluids of infected people. Funeral rites, where families traditionally touch and wash the bodies of the deceased, have historically served as transmission points during past outbreaks.

Ebola emerged as a recognized pathogen in 1976, first identified in what was then called Zaire, in the northern region near the river that would give the virus its name. Scientists have since catalogued six distinct strains: Zaire, Sudan, Bundibugyo, Reston, Tai Forest, and Bombali. The virus originates in fruit bats, which harbor the disease without becoming ill themselves, though other animals—great apes, antelopes, porcupines—can carry it and transmit it to humans. Once it reaches a human population, the disease spreads through the kind of close contact that defines community life: caring for the sick, preparing bodies for burial, sharing space with infected family members.

The mortality rate among those who contract Ebola ranges between forty and seventy percent, according to WHO data from recent outbreaks in the DRC. After an incubation period of two to twenty-one days, infection announces itself with sudden fever, fatigue, muscle pain, headache, and sore throat. These initial symptoms give way to vomiting, diarrhea, abdominal pain, and rash. As the disease progresses, kidney and liver function deteriorate, sometimes accompanied by internal and external bleeding. Those who survive often carry lasting damage: arthritis, vision problems, eye inflammation, and hearing loss.

The medical response hinges partly on what vaccines and treatments exist. For the Zaire strain, two vaccines are available—Ervebo, made by Merck, and Sabdeno, from Johnson & Johnson. Two monoclonal antibodies, which significantly reduce mortality, also exist for Zaire. The Sudan strain, however, remains less protected; three candidate vaccines have been in testing since late 2022 after WHO approval. For now, treatment relies on supportive care: rehydration and blood transfusions to sustain patients through the acute phase of illness.

A complication emerged from research published in the journal Nature: the virus can remain dormant in survivors, only to reactivate years later and spark a new outbreak. This means that even those who recover carry the potential to reignite transmission. The current outbreak, centered in eastern DRC across three health zones, represents the kind of situation that demands rapid containment, careful contact tracing, and sustained attention to neighboring regions where the virus could take hold. The declaration by the WHO signals that the world is watching, but the real work—stopping transmission, treating the sick, protecting the vulnerable—falls to health workers and communities on the ground.